Mesoblast (MESO) - 2025 Q1 - Quarterly Report

Exhibit 99.1 ¶mesoblast ANNUALREPORT 2024 GLOBAL LEADER IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASES CONTENTS CORPORATE GOVERNANCE Mesoblast Limited and its Board of Directors are committed to implementing and achieving an effective corporate governance framework to ensure that the Company is managed effectively and in an honest and ethical way. The Company's Corporate Governance Statement for the financial year ending 30 June 2024 has been approved by the Board and is available on our website ...